Generic Biologics Still on Congress' Radar Screen : A bill that would allow for the production of generic insulin likely would not affect most insulin users.

In addition to the Congressional bill, a group of governors petitioned the FDA last summer, urging it to release its guidelines for the approval of follow-on biologics, which the agency began in 2002. The petition was supported by various consumer groups and the Generic Pharmaceutical Association, but the agency has not yet responded.